SPRY
ARS Pharmaceuticals, Inc
NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY
$8.26
+5.36% today
Updated 2026-04-30
Market cap
$788.42M
P/E ratio
—
P/S ratio
9.36x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$7 – $19
Volume
1.5M
ARS Pharmaceuticals, Inc (SPRY) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-16.88M | $-18.90M | $9.07M | $-17.56M | $-40.08M | $-59.27M | $13.55M | $-170.87M |
| Capital expenditures | $449000.00 | $96000.00 | $917000.00 | $55000.00 | $199000.00 | $175000.00 | $563000.00 | $339000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $3.54M | $2.83M | $5.84M | $9.23M | $14.53M | $22.09M |
| Free cash flow | $-17.32M | $-18.99M | $8.15M | $-17.62M | $-40.28M | $-59.44M | $12.98M | $-171.21M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $150.46M | — | — | — |